Europe
Biopharma companies make changes to their C-suite leadership teams, with hires at uBiome, Enzyre, Sobi, Amylyx, Mission Therapeutics, and more.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Biopharma has several unique challenges, but one of them is the patent cliff. In an industry where only about one in 10 compounds actually makes it to market on average, those drugs aren’t able to stay on the market very long before their patents end and generic competition begins.
For those select few who achieve the role of chief executive officer of a multi-national corporation, the compensation packages are typically quite large – especially when compared to the average salaries of company employees.
There has been a string of news stories about how big pharma is teaming up with various artificial intelligence (AI) companies to leverage real-world data and speed drug development.
In its announcement, GSK said the decision to cut the two programs were made following an analysis of available research results, including interim data from an ongoing Phase I study of the flu vaccine.
Dengvaxia is approved for dengue disease caused by serotypes 1-4 in people 9 through 16 years of age who are living in areas of the U.S. who have had a laboratory-documented previous infection.
Attain Stability(TM) Quad MRI SureScan(TM) Lead Designed for Precise Placement and Stability
Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors
Pharma, biotech and life science companies from across the globe share data and progress on pipelines and other company events.
PRESS RELEASES